mRNA-1010 Influenza Vaccine Shows Enhanced Antibody Response in Older Adults
The investigational mRNA-1010 influenza vaccine has demonstrated superior antibody responses compared to a standard-dose vaccine in adults aged 50 years and older. This finding comes from a phase 3, randomized, double-blind, active-controlled FLUENT trial involving 40,805 participants during the 2024 to 2025 Northern Hemisphere influenza season. Researchers assessed humoral immunogenicity in a prespecified subset of patients from North American sites, measuring hemagglutination inhibition (HAI) antibody responses at baseline and 29 days post-vaccination. The mRNA-1010 vaccine, which targets influenza A/H1N1, A/H3N2, and B/Victoria strains, showed significantly higher geometric mean titers, geometric mean fold rises, and seroconversion rates across all three strains. For instance, seroconversion rates for mRNA-1010 were 55.0% for A/H1N1 compared to 27.1% for the standard-dose vaccine. These results, published in Open Forum Infectious Diseases, support mRNA-1010 as a promising enhanced seasonal influenza vac...